Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects
To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. [14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine sam...
Saved in:
Published in | International journal of clinical pharmacology and therapeutics Vol. 53; no. 10; p. 838 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.10.2015
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects.
[14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine samples were collected predose and at various intervals postdose. Naloxegol and its metabolites were quantified or identified by liquid chromatography with radiometric or mass spectrometric detection. Pharmacokinetic parameters were calculated for each subject, and metabolite identification was performed by liquid chromatography with parallel radioactivity measurement and mass spectrometry.
Naloxegol was rapidly absorbed, with a maximum plasma concentration (geometric mean) of 51 ng/mL reached before 2 hours after dosing. A second peak in the observed naloxegol and [14C] plasma concentration-time profiles was observed at ~3 hours and was likely due to enterohepatic recycling of parent naloxegol. Distribution to red blood cells was negligible. Metabolism of [14C]-naloxegol was rapid and extensive and occurred via demethylation and oxidation, dealkylation, and shortening of the polyethylene glycol chain. Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing. Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively. Unchanged naloxegol accounted for ~1/4 of the radioactivity recovered in feces.
Naloxegol was rapidly absorbed and cleared via metabolism, with predominantly fecal excretion of parent and metabolites. |
---|---|
AbstractList | To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects.
[14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine samples were collected predose and at various intervals postdose. Naloxegol and its metabolites were quantified or identified by liquid chromatography with radiometric or mass spectrometric detection. Pharmacokinetic parameters were calculated for each subject, and metabolite identification was performed by liquid chromatography with parallel radioactivity measurement and mass spectrometry.
Naloxegol was rapidly absorbed, with a maximum plasma concentration (geometric mean) of 51 ng/mL reached before 2 hours after dosing. A second peak in the observed naloxegol and [14C] plasma concentration-time profiles was observed at ~3 hours and was likely due to enterohepatic recycling of parent naloxegol. Distribution to red blood cells was negligible. Metabolism of [14C]-naloxegol was rapid and extensive and occurred via demethylation and oxidation, dealkylation, and shortening of the polyethylene glycol chain. Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing. Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively. Unchanged naloxegol accounted for ~1/4 of the radioactivity recovered in feces.
Naloxegol was rapidly absorbed and cleared via metabolism, with predominantly fecal excretion of parent and metabolites. |
Author | Bui, Khanh Sostek, Mark Hutchison, Michael She, Fahua Brunnström, Åsa |
Author_xml | – sequence: 1 givenname: Khanh surname: Bui fullname: Bui, Khanh – sequence: 2 givenname: Fahua surname: She fullname: She, Fahua – sequence: 3 givenname: Michael surname: Hutchison fullname: Hutchison, Michael – sequence: 4 givenname: Åsa surname: Brunnström fullname: Brunnström, Åsa – sequence: 5 givenname: Mark surname: Sostek fullname: Sostek, Mark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26329350$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKxDAYRrMYcS4KPoHkAaaa_E2bZjkUbzCgC12JDLn8cTqkTWlamHl7kdHVx-HAgW9JZl3skJAbzu4KwcV9_QYMQJYzsmBKlBlXZTEny5QOjEFRSHVJ5lDmoPKCLYjZmBSHfmxit6auSePQmOlMLY7axNCkdk115yge7YC_ikZPP7mov7KgDQZ0tNMhHvE7Btp0dI86jPsTTZM5oB3TFbnwOiS8_tsV-Xh8eK-fs-3r00u92WY2lzBmEiulwVuWc6ukt1payXN0zCFWBnihGViBvjLC65wL5z0qzcF6W1Xcc1iR23O3n0yLbtcPTauH0-7_LPwAFFdXBQ |
CitedBy_id | crossref_primary_10_5056_jnm18079 crossref_primary_10_1002_cpdd_335 crossref_primary_10_1093_jat_bkx104 crossref_primary_10_1016_j_ejps_2018_02_008 crossref_primary_10_1002_psp4_12229 crossref_primary_10_1007_s11912_015_0481_x crossref_primary_10_1002_jcph_693 crossref_primary_10_1016_j_clinbiochem_2019_03_006 crossref_primary_10_1097_FAD_0000000000000023 crossref_primary_10_1002_psp4_12070 crossref_primary_10_1007_s40262_016_0479_z crossref_primary_10_1177_1756283X16648869 crossref_primary_10_4155_bio_2016_0253 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.5414/CP202276 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 26329350 |
Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
GroupedDBID | --- .GJ 36B 53G 5GY 7X7 88E 8FI 8FJ ABJNI ABUWG ACGFO ACGFS ADBBV AENEX AFFNX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CGR CUY CVF DLWAR EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK M1P MK0 NPM P2P PHGZT PQQKQ PROAC PSQYO SJN SV3 UKHRP VDS ZGI ZXP ~4P |
ID | FETCH-LOGICAL-c372t-7e89a2fc031c97fca7c713ed0dee8b215a02c4ef8b4fa314dffe9a12cfc881f12 |
ISSN | 0946-1965 |
IngestDate | Thu Apr 03 06:54:07 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c372t-7e89a2fc031c97fca7c713ed0dee8b215a02c4ef8b4fa314dffe9a12cfc881f12 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/4564822 |
PMID | 26329350 |
ParticipantIDs | pubmed_primary_26329350 |
PublicationCentury | 2000 |
PublicationDate | 2015-10-01 |
PublicationDateYYYYMMDD | 2015-10-01 |
PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | International journal of clinical pharmacology and therapeutics |
PublicationTitleAlternate | Int J Clin Pharmacol Ther |
PublicationYear | 2015 |
SSID | ssj0025579 |
Score | 2.1575322 |
Snippet | To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 838 |
SubjectTerms | Aged Carbon Radioisotopes Humans Male Middle Aged Morphinans - adverse effects Morphinans - pharmacokinetics Narcotic Antagonists - pharmacokinetics Polyethylene Glycols - adverse effects Polyethylene Glycols - pharmacokinetics Tissue Distribution |
Title | Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26329350 |
Volume | 53 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2cOGCKO9SkA-0lyaQh5M4x7aAKiTQSmylSghVjh9spTZZkV2pyx_j7zETO4lZHgIuUTZeJbG_b-2Z2ZnPhDxnkTRcqSQERA2GbvKwVEKFqmCiyjSsEd1mMO_e5yen7O1ZdjaZfPOyllbL6oX8-su6kv9BFa4Brlgl-w_IDjeFC3AO-MIREIbjX2F8WLXNl-43jyOlUAPXbV-Fn6_0EhC-xNQKl6KpryUWLVoTcS87itnxXvYqBCLA4qMO4HnNtf7coAyHK5BcH7SrCkM1rW_F_hhG9MQnhjrLxaiIve6TNPs6rzEwv7KpBHNRD0HpD3ObbyzmKzFSDqh10f6c59-FEcACh37jH_5HeddTPOVZK_yARpwNqXFDZJLlIQod-pO0VRTuyRh5Uy636jCbSwFub44Sw9MERRJz_ysA4uKqowSK1ZepVb79c-uGKHfftEW2wD3B_VYxSOT8_CxzEo-uH1bzGF_oZf86qEHtbrHhz3R2zewOue0cEnpo2bVNJrq-S_anFr91QGcecAHdp1MP2XukGikYUJ-AAR3pF1BgAB3IRxtDPwL1PvXEowPx6EVNHfFoT7z75PTN69nxSei27QhlWiTLsNC8FImRsFzIsjBSFLKIU60ipTWvwMQUUSKZNrxiRqQxU8boUsSJNJLz2MTJA3Kjbmr9iNBMFIWKcxlxUTBdYuBbK8ONBi-iUil7TB7asTtfWG2W835Ud37b8oTcGlm3S24amAz0U7Asl9WzDsfvmAl6xQ |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absorption%2C+distribution%2C+metabolism%2C+and+excretion+of+%5B14C%5D-labeled+naloxegol+in+healthy+subjects&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Bui%2C+Khanh&rft.au=She%2C+Fahua&rft.au=Hutchison%2C+Michael&rft.au=Brunnstr%C3%B6m%2C+%C3%85sa&rft.date=2015-10-01&rft.issn=0946-1965&rft.volume=53&rft.issue=10&rft.spage=838&rft_id=info:doi/10.5414%2FCP202276&rft_id=info%3Apmid%2F26329350&rft_id=info%3Apmid%2F26329350&rft.externalDocID=26329350 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon |